TY  - CONF
AU  - Grande, E.
AU  - Garcia-Carbonero, R.
AU  - Teule, A.
AU  - Benavent Vinuales, M.
AU  - Jimenez-Fonseca, P.
AU  - Molina-Cerrillo, J.
AU  - Lopez, C.
AU  - Custodio, A.
AU  - Hierro, C.
AU  - Gallego, J.
AU  - Alonso, V.
AU  - Carmona-Bayonas, A.
AU  - Llanos, M.
AU  - Sevilla, I.
AU  - Hernando, J.
AU  - Lista, F.
AU  - Anton Pascual, B.
AU  - Ruffinelli, J. C.
AU  - Gallego Jimenez, I.
AU  - Capdevila, J.
PY  - 2021
DO  - 10.1016/j.annonc.2021.08.710
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/27029
T2  - Annals of oncology
AB  - Antiangiogenic agents have demonstrated antitumor properties in endocrine malignancies regardless of their primary origin. Experience with immune-checkpoint inhibitors is limited in this area and early results when used as single agents are...
LA  - en
PB  - Elsevier
KW  - cabozantinib
KW  - Endocrine Gland Neoplasms
KW  - atezolizumab
KW  - Angiogenesis Inhibitors
KW  - Immune Checkpoint Inhibitors
TI  - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multicohort phase II trial (CABATEN trial / GETNE-T1914)
TY  - conference output
VL  - 32
ER  -